Physician profile
Mark Y Johnson
NPI 1861421372
$1,414.03
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $458 · 2020: $62.31 · 2021: $297 · 2022: $280 · 2023: $316.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $316.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $316.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $277.82 | 2019-2022 | |
| Novo Nordisk INC | $239.49 | 2022-2023 | Wegovy |
| Boston Scientific Corporation | $193.59 | 2019-2021 | |
| Cook Medical LLC | $178.69 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $118.99 | 2023 | Terlivaz |
| Janssen Biotech, INC. | $117.27 | 2021 | |
| Braintree Laboratories, INC. | $71.52 | 2021 | |
| Intercept Pharmaceuticals, INC. | $60.00 | 2023 | Ocaliva |
| Exelixis INC. | $39.06 | 2019 | |
| Amag Pharmaceuticals, INC. | $24.21 | 2021 | |
| Erbe USA INC | $20.40 | 2019 | |
| Ferring Pharmaceuticals INC. | $16.72 | 2023 | Menopur |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.49 | 2020 | |
| Redhill Biopharma INC. | $16.36 | 2020 | |
| Abbvie INC. | $16.28 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Romark Laboratories, Lc | $7.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.